Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancer. 2012 Jul 15;118(14):3531-7. doi: 10.1002/cncr.26593. Epub 2011 Dec 2.
Fluorescence in situ hybridization can detect genomic abnormalities in up to 80% of cases and provides prognostic information on patients with chronic lymphocytic leukemia (CLL). Although 13q deletion as the sole abnormality has been found to confer a favorable prognosis, there are little data as to whether there is a difference in prognostic value between monoallelic versus biallelic deletion of 13q.
The authors reviewed the electronic database for patients with CLL who carried the 13q deletion as the sole abnormality and presented to The University of Texas MD Anderson Cancer Center (MDACC). Untreated patients were separated into 2 groups: those having monoallelic versus those with biallelic deletion of 13q. Using Mann-Whitney, chi-square, and Kaplan-Meier analysis, the baseline quantitative and qualitative variables for each group, along with the time from presentation to MDACC to treatment, were compared.
A total of 176 patients were identified; 143 patients had a monoallelic deletion of 13q, whereas 33 patients had a biallelic deletion. The only significantly different values between the groups were albumin (4.5 g/dL vs 4.4 g/dL; P = .01) and zeta-chain-associated protein kinase 70 (ZAP70) expression (1.7% vs 4.8%; P = .010). The median time from fluorescence in situ hybridization analysis to treatment in both the monoallelic and biallelic groups had not been reached (P = not significant).
Except for inconsequential differences in albumin and ZAP70 expression, there was no difference in the baseline characteristics between patients with CLL who had monoallelic or biallelic deletion of 13q. In addition, there was no significant difference in endpoints, including time to treatment.
荧光原位杂交技术可以检测高达 80%的病例的基因组异常，并为慢性淋巴细胞白血病（CLL）患者提供预后信息。虽然已经发现 13q 缺失作为唯一异常可提供有利的预后，但对于 13q 单等位基因缺失与双等位基因缺失之间是否存在预后价值差异的数据较少。
作者检索了在德克萨斯大学 MD 安德森癌症中心（MDACC）就诊的携带 13q 缺失作为唯一异常的 CLL 患者的电子数据库。未经治疗的患者被分为两组：单等位基因缺失组和双等位基因缺失组。使用 Mann-Whitney、卡方和 Kaplan-Meier 分析，比较每组的基线定量和定性变量，以及从就诊到 MDACC 接受治疗的时间。
共确定了 176 例患者；143 例患者存在 13q 单等位基因缺失，而 33 例患者存在 13q 双等位基因缺失。两组之间唯一显著不同的数值是白蛋白（4.5g/dL 与 4.4g/dL；P=.01）和 ζ 链相关蛋白激酶 70（ZAP70）表达（1.7%与 4.8%；P=.010）。单等位基因和双等位基因缺失组的从荧光原位杂交分析到治疗的中位时间均未达到（P=无统计学意义）。
除了白蛋白和 ZAP70 表达的无关差异外，13q 单等位基因或双等位基因缺失的 CLL 患者的基线特征无差异。此外，包括治疗时间在内的终点没有显著差异。
